- Conditions
- MDD, Depression
- Interventions
- Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 4,112
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV, Contraception
- Interventions
- TFV IVR, TFV/LNG IVR, Placebo IVR
- Drug · Other
- Lead sponsor
- CONRAD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Smoking Cessation
- Interventions
- Headspace, TEDTalk
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anxiety
- Interventions
- Anxiety Self-Management, Patient preferred relaxing music, Control 1: Noise-cancelling headphones, Control 2: Standard of Care
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dry Eye Disease
- Interventions
- 0.003% AR-15512 ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Great Saphenous Vein (GSV) With Venous Reflux Disease
- Interventions
- VenaSeal SCS, ClosureFast Radiofrequency Ablation (RFA), Roll-In (VenaSeal SCS)
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Diego, California • Greenwood Village, Colorado + 6 more
- Conditions
- Mucociliary Clearance
- Interventions
- HFO-1234ze(E), HFA-134a
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
- Conditions
- Colon Adenocarcinoma, Colorectal Cancer
- Interventions
- TAS-102, Irinotecan, Standard Treatment, Signatera MRD ctDNA Assay
- Drug · Combination Product · Diagnostic Test
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Refractive Errors, Ametropia
- Interventions
- Lehfilcon A contact lenses, Senofilcon A contact lenses, Comfilcon A contact lenses, Hydrogen peroxide-based cleaning and disinfecting solution
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Longwood, Florida • Maitland, Florida • Warwick, Rhode Island + 1 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Omega 3 Fatty Acids, Corn oil
- Drug · Dietary Supplement
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myopia
- Interventions
- Experimental- Soflens, Marketed - Soflens
- Device
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Interventions
- ReMMi-D Digital Therapeutic
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Amputation
- Interventions
- Experimental prosthetics foot (K3 Promoter)
- Device
- Lead sponsor
- Tensegrity Prosthetics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Arvada, Colorado
- Conditions
- Rheumatoid Arthritis
- Interventions
- PF-06650833, Placebo, Tofacitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 15
- States / cities
- Tuscaloosa, Alabama • Tucson, Arizona • Clearwater, Florida + 9 more
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stroke
- Interventions
- Music Playing Task
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Telemedicine, Running, Knee, Pain
- Interventions
- Telehealth Gait Retraining, Standard Physical Therapy Treatment, Return to Running Protocol, At Home Exercise Program
- Procedure
- Lead sponsor
- Keller Army Community Hospital
- Federal
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- West Point, New York
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
- Interventions
- Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more
- Conditions
- Measles; Mumps; Rubella; Chickenpox, Measles
- Interventions
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 801 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more
- Conditions
- Immunization, HPV Infection, Human Papillomavirus
- Interventions
- 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
- Biological
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 27 Years to 45 Years · Female only
- Enrollment
- 618 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Overweight, Obese, Type 1 Diabetes Mellitus
- Interventions
- CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo
- Drug · Device
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Concord, California • Escondido, California • Aurora, Colorado + 17 more
- Conditions
- Enterotoxigenic Escherichia Coli Infection, Diarrhea
- Interventions
- VLA1701, Placebo, Challenge Strain
- Biological · Other
- Lead sponsor
- Valneva Austria GmbH
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
- Interventions
- Brigatinib, Neratinib, Retifanlimab, Bevacizumab
- Drug
- Lead sponsor
- Scott R. Plotkin, MD, PhD
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Miami, Florida • Indianopolis, Indiana + 3 more
- Conditions
- Ovarian Cancer, Malignant Female Reproductive System Neoplasm, Cancer, Ovarian Tumor, Ovarian Epithelial Cancer Recurrent
- Interventions
- DOXIL/CAELYX, ATI-0918
- Drug
- Lead sponsor
- Azaya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Yakima, Washington